Form 4: Tarsus Pharmaceuticals Director Bhaskar Chaudhuri Acquires Stock Options and Restricted Stock Units

Director Bhaskar Chaudhuri of Tarsus Pharmaceuticals acquired stock options and restricted stock units (RSUs) as part of his compensation for serving as a non-employee director.

Summary

• Bhaskar Chaudhuri, a director at Tarsus Pharmaceuticals, received stock options and restricted stock units (RSUs) on June 13, 2024.
• The stock options grant him the right to purchase 5,000 shares of common stock at an exercise price of $33.14 per share.
• These options vest fully on June 12, 2025, contingent upon his continued service as a non-employee director.
• Additionally, he received 3,350 RSUs, each representing a contingent right to receive one share of Tarsus Pharmaceuticals' common stock.
• These RSUs also vest fully on June 12, 2025, subject to his continuous service.
• Following these transactions, Chaudhuri directly owns 5,000 stock options and 3,350 RSUs.

Sentiment

Score: 7

Explanation: The document reflects a routine transaction (granting of stock options and RSUs to a director), which is generally viewed as a positive sign of aligning interests between management and shareholders. It's a neutral event with a slightly positive undertone.

Positives

• The grant of stock options and RSUs aligns the director's interests with those of the shareholders, incentivizing him to contribute to the company's success.
• The vesting schedule encourages continued service and commitment from the director.

Future Outlook

The document does not contain any specific forward-looking statements regarding the company's future performance.

Industry Context

This type of equity compensation is standard practice for non-employee directors in publicly traded companies, aligning their interests with shareholders and incentivizing them to contribute to the company's long-term success. It's similar to compensation packages offered to directors at companies like Alcon or Bausch + Lomb, which also operate in the ophthalmology space.

Comparison to Industry Standards

• Equity compensation for non-employee directors is a common practice in the pharmaceutical industry.
• Companies like Alcon and Bausch + Lomb also provide stock options and RSUs to their directors as part of their compensation packages.
• The vesting schedules and exercise prices are generally aligned with industry standards to incentivize long-term commitment and value creation.

Stakeholder Impact

• Shareholders may view this as a positive sign, as it aligns the director's interests with the company's long-term success.
• The director is incentivized to contribute to the company's growth and profitability.

Key Dates